What the FDA labels say about taking them together
Oxycodone and ritonavir
Oxycodone's FDA label of May 6, 2026 names ritonavir in its drug interactions section; ritonavir's label does not name oxycodone itself but warns about its class (Opioids (opioid agonists)). The oxycodone label: “The concomitant use of OXAYDO and CYP3A4 inhibitors can increase the plasma concentration of oxycodone, resulting in increased or prolonged opioid effects. …”
Check it at the source: the oxycodone FDA label on DailyMed (effective May 6, 2026, Rhodes Pharmaceuticals LLC); the ritonavir FDA label on DailyMed (effective July 23, 2026, AbbVie Inc.).
What does the oxycodone label say about ritonavir?
Oxycodone label, drug interactionsMacrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), protease inhibitors (e.g., ritonavir).
Oxycodone label, warnings and precautionsUse or Discontinuation of Cytochrome P450 3A4 Inhibitors and Inducers Concomitant use of oxycodone hydrochloride tablets with a CYP3A4 inhibitor, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may increase plasma concentrations of oxycodone and prolong opioid adverse reactions, which may cause potentially fatal respiratory depression [see Warnings and Precautions (5.3) ], particularly when an inhibitor is added after a stable dose of oxycodone hydrochloride tablets is achieved.
Oxaydo label (Zyla Life Sciences US LLC, January 4, 2026), drug interactionsClinically Significant Drug Interactions with OXAYDO Inhibitors of CYP3A4 and CYP2D6 Clinical Impact: The concomitant use of OXAYDO and CYP3A4 inhibitors can increase the plasma concentration of oxycodone, resulting in increased or prolonged opioid effects. These effects could be more pronounced with concomitant use of OXAYDO and CYP2D6 and CYP3A4 inhibitors, particularly when an inhibitor is added after a stable dose of OXAYDO is … antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), protease inhibitors (e.g., ritonavir) CYP3A4 Inducers
Source: FDA drug label (Roxicodone, NDA021011), SpecGx LLC, effective April 24, 2026 (SPL set 5a8157d3-ba20-4abf-b0d4-6ad141b31d63), via openFDA
Source: FDA drug label (Oxaydo, NDA202080), Zyla Life Sciences US LLC, effective January 4, 2026 (SPL set cff0c64a-63f5-4b3c-909a-cdecf6755cbe), via openFDA
Source: FDA drug label (Oxycodone Hydrochloride), Rhodes Pharmaceuticals LLC, effective May 6, 2026 (SPL set a5162476-1217-41c0-bc7e-0a0f123f069f), via openFDA; the full label on DailyMed
What does the ritonavir label say about oxycodone?
Ritonavir's label does not name oxycodone itself; it warns about its class (Opioids (opioid agonists)):
Ritonavir label, drug interactionsAnalgesics, Opioid: tramadol, propoxyphene, methadone, fentanyl ↑ analgesics ↓ methadone ↑ fentanyl A dose decrease may be needed for these drugs when co-administered with ritonavir.
Source: FDA drug label (Norvir), AbbVie Inc., effective July 23, 2026 (SPL set 2849298e-de6e-47bb-8194-56e075b33fc3), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Oxycodone | Ritonavir | |
|---|---|---|
| Labeled for | Pain | HIV |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.0884 per tablet 5 mg tablet | $0.607 per tablet 100 mg tablet |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once